HHS Logo [ [link removed] ]

Blue Gradient


Change in Preferred Drug List Status for Generic Levalbuterol Inhalation Solution Effective Oct. 31, 2023

In response to the shortage of inhalation solution products with the preferred brand name Xopenex, HHSC removed the non-preferred status from the generic levalbuterol inhalation solution products on the preferred drug list (PDL) effective Oct. 31, 2023. Providers can now prescribe the generic levalbuterol inhalation solution without requiring a PDL prior authorization, allowing clients to continue accessing necessary medication. A list of generic levalbuterol products is available online.

*Reminders:*

* Pharmacy Education Information and Opportunities [ [link removed] ]
* Pharmacy Email Addresses Must Be Current in PEMS [ [link removed] ]








________________________________________________________________________

You have subscribed to get updates about Texas Health and Human Services (HHS). For more information about HHS, please visit our website [ [link removed] ].

________________________________________________________________________

Stay Connected Visit us on Facebook [ [link removed] ] Visit us on YouTube [ [link removed] ] Visit us on Twitter [ [link removed] ] Visit us on Instagram [ [link removed] ] Visit us on Facebook [ [link removed] ]  (en español)  

Bookmark and Share [ [link removed] ]

Subscriber Services
Manage Preferences [ [link removed] ]  |  Unsubscribe [ [link removed] ]  |  Help [ [link removed] ]

________________________________________________________________________

This email was sent to [email protected] using govDelivery Communications Cloud on behalf of: Texas Health and Human Services Commission · 707 17th St, Suite 4000 · Denver, CO 80202 GovDelivery logo [ [link removed] ]